Capital Markets Day

September 8, 2026

ASP ISOTOPES INC.
NASDAQ: ASPI

Agenda

CAPITAL MARKETS DAY
2026

Topic	Speaker	Title
Focus, delivery and value creation	Paul Mann	Executive Chairman & CEO
R&D and engineering	Dr Gerard Puts & Dr. Ignis Ferreira	Principal Process Engineer; Head of R&D
Stable Isotope: Operational Update	Paul Mann	Executive Chairman & CEO
Isotope Legislative Environment	Robert Ainscow	Chief Operating Officer
Nuclear medicine: Radiopharmacies/ PET Labs	Dr. Johannes van Tonder & Paul Mann	Chief Quality Officer, PET Labs; Executive Chairman & CEO
Nuclear medicine: Alpa Theranostics	Martin Magwaza & Paul Mann	President, Alpa Theranostics; Executive Chairman & CEO
Helium and LNG: Noble Africa	Nick Mitchell & Paul Mann	Co-COO, ASP Isotopes; COO, Noble Africa; Executive Chairman & CEO
Electronics	Natalie Grancharov Camacho	VP, Business Development, ASP Isotopes
Nuclear fuels: Quantum Leap Energy	Dr. Ryno Pretorius, Ph.D & Michael Cunniffe	CEO & CFO, Quantum Leap Energy
Financial outlook	Heather Kiessling	Chief Financial Officer
Panel and audience Q&A	Viktor Petkov	Chief Commercial Officer
Closing remarks	Paul Mann	Executive Chairman & CEO

Paul Mann

EXECUTIVE CHAIRMAN & CEO

Paul Mann co-founded ASP Isotopes in September 2021 and serves as the Chairman of the Board of Directors and Chief Executive Officer. Paul has more than 20 years of experience on Wall Street investing in healthcare and chemicals companies. He's worked at Soros Fund Management, Highbridge Capital Management and Morgan Stanley. Paul started his career as a research scientist at Procter and Gamble, and he is named as the inventor of numerous skin creams in the Oil of Olay range of cosmetics. Paul has an MA (Cantab) and a Master of Engineering from Cambridge University, UK where he studied Natural Sciences and Chemical Engineering, and he is a CFA Charterholder.



Dr Gerard Puts

PRINCIPAL PROCESS ENGINEER

Dr Gerard Puts serves as Principle Process Engineer, leading chemical process engineering initiatives across pharmaceuticals, fluorochemical plant engineering, and plasma systems.

Gerard has more than 11 years of industry experience, including over 5 years managing and operating engineering laboratories and chemical pilot plants. He holds a PhD in Chemical Engineering from the University of Pretoria, where his research focused on the design and synthesis of fluorinated polymers.



Dr Ignatius Ferreira

HEAD OF RESEARCH AND DEVELOPMENT

Ignatius Ferreira serves as Head of Research and Development at ASP Isotopes South Africa. He has more than 10 years of experience in industry, previously holding senior positions in the research and development, and engineering fields.

Ignatius has a diverse background in project management, operations management and leading numerous research and development collaboratives. He holds a PhD Chemical Engineering and a BCom Financial Management degree.



Robbert Ainscow

CHIEF OPERATING OFFICER

Robert Ainscow co-founded ASP Isotopes in September 2021 and serves as the Chief Operating Officer. He has more than 20 year's experience in finance, having worked at Morgan Stanley, Bear Stearns and Investec Bank. He started his career in the legal and regulatory department with responsibility for M&A and capital markets oversight. He later transitioned into the capital markets business units and became a Senior Transactor, structuring a broad range of bespoke transactions and funding programs for balance sheet assets and on behalf of clients, more latterly for smaller, early-stage companies in niche markets as an advisor, director, or founder. Robert holds a BA (Law & Modern Languages) from Bristol UWE in the UK.



Dr Johannes Van Tonder

CHIEF QUALITY OFFICER, PET LABS

Dr Johannes van Tonder serves as the Chief Quality Officer at PET Labs, where he oversees quality assurance across the company's radiopharmaceutical manufacturing operations in South Africa. Johannes joined PET Labs in 2014 and has held progressive site-level and executive quality roles, most recently leading the quality initiative to secure GMP licensing for the new Route 21 facility.

He has over 12 years of experience in specialized radiopharmaceutical manufacturing and quality systems. Johannes holds a PhD in Chemistry and has authored 25 peer-reviewed papers and presented at 11 international conferences.



Martin Magwaza

PRESIDENT, ALPA THERANOSTICS

Martin Magwaza serves as President of Alpa Theranostics, a wholly owned subsidiary of ASP Isotopes. Martin has more than 20 years of experience leading scientific and commercial operations for biopharmaceutical and radiopharmaceutical companies. Prior to joining ASP Isotopes, he served as Founding Managing Director of OncoBeta Africa, a specialist radioisotope company. He previously built a successful career holding leadership roles with several multinational pharmaceutical corporations, including AstraZeneca, Pfizer, and Boehringer Ingelheim. Martin holds a Bachelor of Science in Applied Biotechnology from the University of KwaZulu-Natal, completed postgraduate training in E-commerce and Geoinformatics at Nelson Mandela University and Pharmaceutical Marketing at the Chartered Institute of Marketing (UK), and earned an MBA in Technology Entrepreneurship from the Gordon Institute of Business Science at the University of Pretoria.



Nick Mitchell

CO-CHIEF OPERATING OFFICER, ASP ISOTOPES INC & CHIEF OPERATING OFFICER, NOBLE AFRICA

Nick Mitchell serves as Co-Chief Operating Officer of ASP Isotopes Inc and Chief Operating Officer of Noble Africa. He brings almost two decades of upstream oil and gas experience, with a strong track record in developing and commercialising critical gas and helium assets. As co-developer of South Africa's only onshore petroleum production right, Nick has played a central role in delivering the Virginia Gas Project from a stranded resource into a globally significant helium and natural gas reserve.

He chairs the Onshore Petroleum Association of South Africa and serves as a Trustee of the Upstream Training Trust, contributing to industry policy, skills development, and advocacy for the domestic gas sector.



Natalie Grancharov Camacho

VICE PRESIDENT OF BUSINESS DEVELOPMENT, ASP ISOTOPES

Natalie Grancharov Camacho serves as the Vice President of Business Development at ASP Isotopes, leading commercial strategy for specialty isotopically pure materials supporting next-generation technologies, including advanced semiconductors and quantum computing. Natalie has built an impressive career over more than two decades in semiconductor technology, establishing herself as a respected expert within the manufacturing sector. She has held key leadership roles across several technology companies, most recently serving as Director at Intel Corporation. Raised in California's Silicon Valley, Natalie holds a Bachelor of Science in Physics with an emphasis on Semiconductor Device Electronics from the University of California, Davis.



Dr Ryno Pretorius

CHIEF EXECUTIVE OFFICER, QUANTUM LEAP ENERGY

Dr Ryno Pretorius serves as Chief Executive Officer of Quantum Leap Energy (QLE), leading the company's commercialization initiatives in advanced nuclear fuels, including High Assay Low-Enriched Uranium (HALEU) and Lithium-6. Ryno has over 15 years of experience in chemical process engineering and technology scale-up across the nuclear fuel supply chain. He previously worked at the South African Nuclear Energy Corporation (Necsa) at Pelindaba, focusing on fluorination and nuclear fuel production, and spent a decade as Technical Director and CEO of Free Radical Process Design. Ryno holds a BEng, BEng (Hons), MEng, and PhD in Chemical Engineering from the University of Pretoria, specializing in fluorochemical engineering, and completed postgraduate studies in Data Science and Business Analytics at the University of Texas at Austin. He is a registered Professional Engineer (Pr. Eng) and the inventor of two patented chemical processes.



Michael Cunniffe

CHIEF FINANCIAL OFFICER, QUANTUM LEAP ENERGY

Michael Cunniffe serves as Chief Financial Officer of Quantum Leap Energy. Michael brings two decades of life science and financial experience across all development life cycle stages, including executing IPOs and leading corporate growth. Prior to joining Quantum Leap Energy, he was Managing Director UK at Danforth Advisors, providing strategic life science consultancy, including advisory services to ASP Isotopes. He previously served as Chief Financial Officer of Axovia Therapeutics and held finance leadership roles across biopharmaceutical companies including ATAI Life Sciences, Neurogene, and Seqirus. Michael holds a Master's degree in Finance from London Business School.



Heather Kiessling

CHIEF FINANCIAL OFFICER

Heather Kiessling serves as Chief Financial Officer. Heather has more than 30 years of experience leading financial operations for life science and high-tech companies. Prior to joining ASP Isotopes, she served as Managing Director at Danforth Advisors LLC, a life science consulting firm. Heather previously held senior finance leadership roles at Cytonome/ST, LLC and AutoImmune Inc., having started her career as an auditor at Price Waterhouse. She is a Certified Public Accountant (CPA) and holds a BA from the University of California, San Diego, and an MBA from the University of Michigan Graduate School of Business.



Viktor Petkov

CHIEF COMMERCIAL OFFICER

Viktor Petkov serves as Chief Commercial Officer, leading business development with a focus on Europe and North America. Viktor has more than 15 years of experience across investment banking, business development, and early-stage company funding. He has played a key role in originating, structuring, and executing capital markets transactions at HSBC Bank in London and managed the expansion of financial products at Bloomberg LP. Viktor also headed the Capital Markets function for the UK's first online mortgage lender and most recently served as Head of Funding for a prominent UK-based financial technology company. He holds an MSc in Finance and Investment from Queen Mary University of London and a BSc in Economics from the University of Magdeburg, Germany.

